RT Journal Article
SR Electronic
T1 Exposures to different SARS-CoV-2 spike variants elicit neutralizing antibody responses with differential specificity towards established and emerging strains
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.09.08.21263095
DO 10.1101/2021.09.08.21263095
A1 Laurie, Matthew T
A1 Liu, Jamin
A1 Sunshine, Sara
A1 Peng, James
A1 Black, Douglas
A1 Mitchell, Anthea M
A1 Mann, Sabrina A
A1 Pilarowski, Genay
A1 Zorn, Kelsey C
A1 Rubio, Luis
A1 Bravo, Sara
A1 Marquez, Carina
A1 Petersen, Maya
A1 Havlir, Diane
A1 DeRisi, Joseph
YR 2021
UL http://medrxiv.org/content/early/2021/09/12/2021.09.08.21263095.abstract
AB The wide spectrum of SARS-CoV-2 variants with phenotypes impacting transmission and antibody sensitivity necessitates investigation of the immune response to different spike protein versions. Here, we compare the neutralization of variants of concern, including B.1.617.2 (Delta) in sera from individuals exposed to variant infection, vaccination, or both. We demonstrate that neutralizing antibody responses are strongest against variants sharing one or more spike mutations with the immunizing exposure. We also observe that exposure to multiple spike variants increases the breadth of variant cross-neutralization. These findings contribute to understanding the relationship between exposures and antibody responses and may inform booster vaccination strategies.Competing Interest StatementDr. DeRisi is a member of the scientific advisory board of The Public Health Company, Inc., and is scientific advisor for Allen & Co. Dr. DeRisi also reports options granted for service on the Scientific Advisory Board of The Public Health Company. None of the other authors have any potential conflicts.Funding StatementThis work was supported by the University of California San Francisco COVID fund [to J.D., M.L., J.L., and S.S.]; the National Institutes of Health [grant number UM1AI069496 to D.H.; and grant number F31AI150007 to S.S.]; the Chan Zuckerberg Biohub [to J.D. and D.H.]; and the Chan Zuckerberg Initiative [to J.D. and D.H.].Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The UCSF Committee on Human Research determined that the study met criteria for public health surveillance. All participants provided informed consent for COVID-19 testing, viral sequencing, and serum collection.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesRelevant viral genome sequences have been deposited in GISAID. https://www.gisaid.org